Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CUPR
Upturn stock ratingUpturn stock rating

Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)

Upturn stock ratingUpturn stock rating
$9.4
Last Close (24-hour delay)
Profit since last BUY56.67%
upturn advisory
Strong Buy
BUY since 47 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: CUPR (4-star) is a STRONG-BUY. BUY since 47 days. Profits (56.67%). Updated daily EoD!

Upturn Star Rating

rating

Above Average Performance

These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.

Number of Analysts

rating

0 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

Analysis of Past Performance

Type Stock
Historic Profit 56.67%
Avg. Invested days 47
Today’s Advisory Strong Buy
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 5.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta -
52 Weeks Range 3.51 - 6.98
Updated Date 06/12/2025
52 Weeks Range 3.51 - 6.98
Updated Date 06/12/2025
Dividends yield (FY) -
Basic EPS (TTM) -

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -
Return on Equity (TTM) -

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating -
Shares Outstanding -
Shares Floating -
Percent Insiders -
Percent Institutions -

ai summary icon Upturn AI SWOT

Cuprina Holdings (Cayman) Limited Class A Ordinary Shares

stock logo

Company Overview

overview logo History and Background

There is no publicly available information for a company called 'Cuprina Holdings (Cayman) Limited Class A Ordinary Shares' in the US stock market. This response provides a template, assuming it's a hypothetical or private company.

business area logo Core Business Areas

  • Segment Name 1: [Description of Segment 1]
  • Segment Name 2: [Description of Segment 2]

leadership logo Leadership and Structure

Outline leadership team and organizational structure here.

Top Products and Market Share

overview logo Key Offerings

  • Product Name 1: [Description of Product 1, include any market share data or number of users or revenue from this product. Who are the competitors for this product]
  • Product Name 2: [Description of Product 2, include any market share data or number of users or revenue from this product. Who are the competitors for this product]

Market Dynamics

industry overview logo Industry Overview

Summarize industry conditions here.

Positioning

Explain the company's competitive position.

Total Addressable Market (TAM)

What is the expected total market value? How is Cuprina Holdings (Cayman) Limited Class A Ordinary Shares positioned with respect to this TAM?

Upturn SWOT Analysis

Strengths

  • Strength 1
  • Strength 2
  • Strength 3

Weaknesses

  • Weakness 1
  • Weakness 2
  • Weakness 3

Opportunities

  • Opportunity 1
  • Opportunity 2
  • Opportunity 3

Threats

  • Threat 1
  • Threat 2
  • Threat 3

Competitors and Market Share

competitor logo Key Competitors

Competitive Landscape

Evaluate advantages and disadvantages compared to competitors.

Growth Trajectory and Initiatives

Historical Growth: Discuss growth trends over the past years.

Future Projections: Provide projections for future growth based on analyst estimates.

Recent Initiatives: Highlight recent strategic initiatives.

Summary

The lack of available data makes a complete evaluation impossible. If this were a real company, strong fundamentals and clear competitive advantages would be key for success. They would need to focus on maintaining a healthy balance sheet, generating cash flow, and capitalizing on growth opportunities, while also mitigating threats. Consistent shareholder returns will be important

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Hypothetical analysis based on the provided template.

Disclaimers:

This analysis is based on limited data and is for illustrative purposes only. It should not be used as investment advice.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Cuprina Holdings (Cayman) Limited Class A Ordinary Shares

Exchange NASDAQ
Headquaters -
IPO Launch date 2025-04-10
CEO & Director Mr. Yong Qi Quek
Sector Healthcare
Industry Medical Instruments & Supplies
Full time employees 14
Full time employees 14

Cuprina Holdings (Cayman) Limited, a biomedical and biotechnology company, focuses on the development and commercialization of products for the management of chronic wounds. The company manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products used as a biological debridement tool for chronic wounds under the MEDIFLY brand name. It is also developing collagen dressings, including sponges, particles, and hydrogels using bullfrog collagen derived from the valorization of abattoir waste; and products using medical leeches for wound treatment. The company was founded in 2019 and is based in Singapore. Cuprina Holdings (Cayman) Limited operates as a subsidiary of Cuprina Holding Pte. Ltd.